Health-Related Quality Of Life Impact Of Triple Combinations Of Olmesartan Medoxomil, Amlodipine Besylate And Hydrochlorothiazide In Subjects With Hypertension

A secondary objective of a phase-III study spanning 54 weeks was to measure changes in the health-related quality of life (HRQoL) of 2,690 patients ≥18 years of age with moderate-to-severe hypertension who ended up receiving one of six doses of olmesartan/amlodipine/hydrochlorothiazide (OLM/AML/HCTZ) using the MINICHAL and EQ5D instruments.
Source: Value in Health - Category: Global & Universal Authors: Source Type: research